AMD Treatment Pipeline
Peer-reviewed articles on investigational therapies and a look at how they will affect your practice.

Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration
By:  Stephan Michels, M.D.; Philip J. Rosenfeld, M.D., PhD.

Anecortave Acetate: Treatment for Age-Related Macular Degeneration
By:  Allen C. Ho, M.D.

Pegaptanib Sodium Therapy for Exudative Age-Related Macular Degeneration
By:  Lawrence J. Singerman, M.D., F.A.C.S.; Joan H. Hornik, A.B.

Will the AMD Therapies Now in Clinical Trials Deliver What They Promise?
By:  Kay T. Adams
Two specialists discuss the possible impact on practice management and what we still need to know about the new drugs.

Intravitreal Steroid Injections for Macular Edema: Way of the Future?
By:  Sophie J. Bakri, M.D.; Peter K. Kaiser, M.D.

Intravitreal Injections: A Coding and Reimbursement Review
By:  Kevin J. Corcoran, C.O.E., C.P.C., F.N.A.O.
The number of claims your practice files will increase as new therapeutic substances become available.

Do the Advantages of 25-Gauge Vitrectomy Outweigh the Disadvantages?
By:  Carl C. Awh, M.D.
One surgeon explains why his answer is yes.

The Economics of Visudyne
The latest cost and reimbursement changes were a net positive, but attention to efficiency remains crucial.

Upfront
By:  Jason S. Slakter, M.D.
A New Forum for Retina Specialists

Insights from Industry
By:  Flemming Orsnkov, M.D., M.P.H.; Cynthia Hogan
Diabetic Retinopathy: a Formidable Challenge

Subspecialty News

Clinical Trial Update

New Products & Services

Imaging
Assessing RPE Function with Autofluorescence